← Leaderboards
Karl-Dimiter Bissig
Duke University
$5,231,801
Attributed
$6,143,796
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $960.5K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,143,796 · 4
By mechanism
R01$5,906,178 · 3
R56$237,618 · 1
Top collaborators
- Aravind Asokan3 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoLiverDesignMetabolicGenome EditingCellsGene TherapyEnzymesMouse ModelHepatocyteLiver DiseasesHumanized MouseSafetyMonitorGenesExcisionCrispr/Cas TechnologyDependovirusMetabolic DiseasesMutationGuide RnaInnovationAnimal ModelMediating
Grant awards (13)
Dissecting AAV silencing in humanized mice$616,213
R01 · FY2025 · DK · contact PI
Dissecting AAV silencing in humanized mice$591,564
R01 · FY2024 · DK · contact PI
Dissecting AAV silencing in humanized mice$616,213
R01 · FY2023 · DK · contact PI
Therapeutic potential of CRISPR/Cas9 genome engineering in humanized mouse$549,652
R01 · FY2020 · HL · contact PI
Therapeutic pathway reprogramming for metabolic liver disease$355,195
R01 · FY2020 · DK · contact PI
Therapeutic potential of CRISPR/Cas9 genome engineering in humanized mouse models$599,025
R01 · FY2019 · HL · contact PI
Therapeutic pathway reprogramming for metabolic liver disease$326,431
R01 · FY2019 · DK · contact PI
Therapeutic pathway reprogramming for metabolic liver disease$35,080
R01 · FY2019 · DK · contact PI
Therapeutic potential of CRISPR/Cas9 genome engineering in humanized mouse models$599,025
R01 · FY2018 · HL · contact PI
Therapeutic pathway reprogramming for metabolic liver disease$356,625
R01 · FY2018 · DK · contact PI
Therapeutic potential of CRISPR/Cas9 genome engineering in humanized mouse models$599,025
R01 · FY2017 · HL · contact PI
Therapeutic pathway reprogramming for metabolic liver disease$237,618
R56 · FY2017 · DK · contact PI
Therapeutic potential of CRISPR/Cas9 genome engineering in humanized mouse models$662,130
R01 · FY2016 · HL · contact PI